Sanofi
Fused pentacyclic imidazole derivatives as modulators of TNF activity
Last updated:
Abstract:
A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNF.alpha. activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
14 Mar 2018
Issue date:
23 Mar 2021